NESS ZIONA, Israel (March 13, 2015) – Kamada Ltd. (Nasdaq and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces that the Company has strengthened its senior leadership team with the appointment of Eran Schenker, M.D. to the newly created position of Vice President-Medical Director Dr. Schenker will report to David Tsur, co-founder and CEO of Kamada.
“We are very pleased to welcome Dr. Schenker to our senior management team as he brings relevant experience and significant expertise in areas key to Kamada's continued growth and leadership in plasma-derived protein therapeutics,” stated Mr. Tsur. “As we expand our core commercial business, increase our revenues and advance our clinical development programs in important areas of unmet medical need such as Type 1 Diabetes and Graft versus Host Disease (GvHD), I am confident Dr. Schenker's contribution will be instrumental in assisting us to achieve our clinical, commercial and corporate objectives. As the leaders in the clinical development of AAT for multiple indications, we are strengthening our medical leadership to support this growing pipeline and to assist us in bringing these innovative therapeutics to patients around the globe. “
Eran Schenker, M.D. – Vice President-Medical Director
Dr. Schenker joins Kamada with more than 15 years of experience in international medical affairs and business development for biotechnology and pharmaceutical companies. Prior to Kamada, from 2007 to 2014, Dr. Schenker was with Neurim Pharmaceuticals, where he initially served as the Medical Director and Business Development Manager and later as Vice President, where he completed the launch of the company's flagship CNS product in more than 40 countries. From 2005 to 2006, Dr. Schenker served as the CEO and Medical Director of Collplant LTD. (TASE: CLPT), a company focused on the development of plant-driven, recombinant, genetically-modified biomaterials technology for the production of human collagen. From 1995 to 2005 Dr. Schenker served as the CEO and Medical Director of MedicTouch Ltd., a mobile health device and application company that designs, develops and markets mobile health applications. Dr. Schenker earned his Bachelor of Science degree in Medical Science and his M.D. from the School of Medicine at the Ben Gurion University in Israel.
About Kamada
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived proteins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia in the U.S. through a strategic partnership with Baxter International. In addition to Glassia, Kamada has a product line of nine other pharmaceutical products that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America, Eastern Europe and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trials in Europe and has initiated Phase 2 clinical trials in the U.S. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing 10 complementary products in Israel that are manufactured by third parties.
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, clinical trials, Intellectual Property, the EMA and U.S. FDA filings and authorizations and timing of clinical trials. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
Contacts:
Gil Efron
CFO
ir@kamada.com
Anne Marie Fields
212-838-3777
afields@lhai.com